Myriad Genetics Inc (MYGN)

Return on total capital

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Earnings before interest and tax (EBIT) (ttm)	US$ in thousands	-79,500	-110,900	-153,300	-232,600	-259,400	-274,000	-258,800	-161,000	-123,700	-120,700	-34,400	-16,200	-47,000	-70,300	-153,500	-209,300	-197,400	-140,100	-116,900	-84,700
Long-term debt	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total stockholders’ equity	US$ in thousands	701,100	731,700	740,500	760,000	783,200	683,400	735,200	835,200	885,800	916,600	947,400	950,100	967,800	968,600	902,500	875,200	879,900	909,300	918,200	967,200
Return on total capital		-11.34%	-15.16%	-20.70%	-30.61%	-33.12%	-40.09%	-35.20%	-19.28%	-13.96%	-13.17%	-3.63%	-1.71%	-4.86%	-7.26%	-17.01%	-23.91%	-22.43%	-15.41%	-12.73%	-8.76%

December 31, 2024 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $-79,500K ÷ ($—K + $701,100K)
= -11.34%

Myriad Genetics Inc has experienced a consistent decline in its return on total capital over the past few years, reflecting negative values ranging from -1.71% to -40.09%. This trend indicates that the company's efficiency in generating profits from its total capital has been weakening over time. The decreasing trend may raise concerns about the company's ability to effectively utilize its capital investments to generate returns for its stakeholders. Myriad Genetics Inc may need to assess and address the factors contributing to this deterioration in order to improve its return on total capital and enhance its overall financial performance.